

The future of antibiotic development: Combating resistance with innovation

Deepak Kumar Bhateja

Department of Pharmacology, Physic
Herbals, Panchkula, Haryana, India

Correspondence:

Deepak Kumar Bhateja,
Physic Herbals 226 Ram Nagar Kalka,
Panchkula - 133 302, Haryana, India.
E-mail: bhatejadeepak@gmail.com

How to cite this article:

Bhateja DK.
The future of antibiotic development:
Combating resistance with innovation.
Innov Pharm Planet (IP-Planet)
2024;12(3):53-55.

Source of Support: Nil.

Conflicts of Interest: None declared.

Date of Submission: 25-08-2024

Date of Revision: 05-09-2024

Date of Acceptance: 15-09-2024

ABSTRACT

Antibiotic resistance is a critical global health threat, driven by the overuse of antibiotics and the slow development of new treatments. This mini-review highlights innovative strategies for combating antimicrobial resistance, including the use of artificial intelligence, CRISPR-based therapies, antimicrobial peptides, and phage therapy. It also addresses economic and regulatory challenges hindering antibiotic innovation and emphasizes the importance of global collaboration and stewardship programs. Novel technologies and multidisciplinary approaches hold promise for revitalizing antibiotic development, ensuring effective treatments for future generations.

Keywords: Antibiotic resistance, antimicrobial peptides, antimicrobial resistance, drug discovery, innovation, phage therapy

Introduction

Antibiotics have been essential in treating bacterial infections since their discovery. However, the efficacy of these drugs is increasingly challenged by the rise of antibiotic-resistant bacteria, a crisis that threatens global public health, making common infections potentially deadly once again. The World Health Organization lists antibiotic resistance as one of the top 10 global public health threats facing humanity. The need for new antibiotics, alongside innovative approaches to counter resistance, is more urgent than ever. This mini-review examines the current challenges in antibiotic development and explores promising innovations to combat antibiotic resistance, including novel drug classes, enhanced diagnostics, and advanced therapeutic approaches.^[1]

The Challenge of Antibiotic Resistance and the Decline in New Antibiotics

Antibiotic resistance occurs when bacteria evolve mechanisms to resist the effects of drugs meant to kill or inhibit them. Overuse and

misuse of antibiotics in health care and agriculture have accelerated this process. Bacteria such as *methicillin-resistant *Staphylococcus aureus**, *carbapenem-resistant *Enterobacteriaceae**, and *multidrug-resistant Tuberculosis* are increasingly prevalent and difficult to treat, often resulting in high mortality rates.^[2]

Historically, the development of new antibiotics was swift, but in recent decades, the pipeline has slowed significantly. The high cost of antibiotic research and development (R and D), combined with lower profitability compared to chronic disease drugs, has led many pharmaceutical companies to reduce or halt antibiotic development efforts. However, without new antibiotics, even routine medical procedures could become high risk due to the threat of untreatable bacterial infections.^[3]

Innovative Approaches to Combat Antibiotic Resistance

Developing new classes of antibiotics

A promising approach to tackling resistance is the development of novel antibiotic classes. Traditional antibiotics, targeting pathways such

Access this article online

Website: <https://innovationaljournals.com/index.php/ip> e-ISSN: 2348-7275

DOI: 10.31690/ipplanet.2024.v012i03.015

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution NonCommercial Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

as cell wall synthesis and protein synthesis, have become increasingly ineffective due to evolved resistance mechanisms. New classes aim to target unique bacterial structures or mechanisms that have not been exploited before, making it more difficult for bacteria to develop resistance.^[4]

One example is the development of antibiotics targeting bacterial virulence factors rather than directly killing bacteria. By disabling the bacteria's ability to cause disease rather than killing them outright, this approach may reduce the selective pressure for resistance. For instance, research into compounds that inhibit bacterial communication systems (quorum sensing) shows promise in rendering bacteria less virulent and more susceptible to immune clearance without promoting resistance.^[5]

Another innovative class involves antimicrobial peptides (AMPs), naturally occurring molecules in many organisms that target bacterial membranes. AMPs offer broad-spectrum activity and a lower likelihood of resistance development. Despite challenges in formulation and stability, advancements in AMP engineering are making these compounds more viable as therapeutic agents.^[6]

Enhancing diagnostic technologies

Accurate and rapid diagnostics are essential for minimizing unnecessary antibiotic use. Traditional culture-based diagnostics can take days, often leading to the use of broad-spectrum antibiotics while waiting for results, which fuels resistance. New diagnostic technologies aim to provide faster, more accurate results, enabling targeted antibiotic therapy.

One example is polymerase chain reaction (PCR)-based diagnostics that can identify bacterial species and resistance genes in hours instead of days. The development of point-of-care diagnostic devices for PCR and other nucleic acid amplification techniques is improving the ability to diagnose bacterial infections quickly and tailor treatments appropriately. In addition, mass spectrometry-based techniques such as matrix-assisted laser desorption/ionization-time of flight are increasingly used in clinical settings for rapid bacterial identification.^[7]

In tandem with these advancements, artificial intelligence is enhancing diagnostic accuracy. Machine learning algorithms trained on large datasets of clinical data can assist health-care providers in identifying the appropriate antibiotics based on specific infection profiles, further reducing inappropriate antibiotic use.^[8]

Phage therapy and other bacteriophage-based innovations

Bacteriophages (phages) are viruses that infect and kill bacteria. Phage therapy, which uses phages to target specific bacterial infections, is a promising alternative to traditional antibiotics. Unlike antibiotics, phages are highly specific to their bacterial hosts, which reduce collateral damage to the beneficial microbiota and minimize the risk of resistance.

Recent advances in genetic engineering have enabled scientists to create synthetic phages that target bacteria more effectively. Companies such as Adaptive Phage Therapeutics are leading efforts in "phage libraries" that can be matched to specific bacterial infections, offering a customized treatment approach. Although still in the early stages, phage therapy could be an effective treatment for multidrug-resistant infections where traditional antibiotics fail.^[9]

Repurposing existing drugs

Drug repurposing offers a cost-effective and time-efficient strategy to find new uses for approved drugs. For example, some nonantibiotic drugs have demonstrated antibiotic effects by targeting bacterial cellular processes. Researchers have found that certain antipsychotic drugs and cancer treatments can exhibit antibacterial properties and may act as adjunct therapies to existing antibiotics, enhancing their efficacy against resistant strains.

Combination therapies, where antibiotics are paired with adjuvant compounds that inhibit bacterial resistance mechanisms, are another promising approach. Beta-lactamase inhibitors, which prevent bacterial enzymes from degrading beta-lactam antibiotics, exemplify this strategy. Ongoing research is exploring additional combinations of drugs that could reinvigorate existing antibiotics against resistant bacteria.

Supporting Antibiotic Development through Policy and Economic Incentives

While scientific innovation is crucial, policy support and economic incentives are equally important to stimulate antibiotic R and D. Initiatives such as the Global Antibiotic R and D Partnership and CARB-X are providing funding and support to accelerate antibiotic development. Policymakers have also proposed "pull" incentives, such as market entry rewards, that would provide financial returns to companies that successfully develop new antibiotics, countering the traditionally low profitability of these drugs.

Similarly, frameworks such as the United States' Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act aim to promote appropriate antibiotic use by reimbursing hospitals for the cost of new antibiotics. These incentives are necessary to ensure that R and D efforts continue and to prevent further attrition of antibiotic research programs.^[10]

Conclusion

The future of antibiotic development requires a shift from traditional methods to innovative approaches that consider the biological complexity of bacteria, the microbiome, and the broader ecological impact of antibiotics. From novel drug classes and enhanced diagnostics to phage therapy and drug repurposing, a new era of antibiotic development is emerging, driven by both scientific advancements and a renewed commitment from policymakers and stakeholders. Only through these combined efforts can we hope to overcome the pressing threat of antibiotic resistance and preserve the efficacy of antibiotics for future generations.

References

1. Cook MA, Wright GD. The past, present, and future of antibiotics. *Sci Transl Med* 2022;14:eabo7793.
2. Chinemerem Nwobodo D, Ugwu MC, Oliseloke Anie C, Al-Ouqaili MT, Chinedu Ikem J, Victor Chigozie U, *et al.* Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. *J Clin Lab Anal* 2022;36:e24655.
3. Church NA, McKillip JL. Antibiotic resistance crisis: Challenges and imperatives. *Biologia* 2021;76:1535-50.
4. Tacconell E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, *et al.* Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis* 2018;18:318-27.
5. Terreni M, Taccani M, Pregnolato M. New antibiotics for multidrug-resistant bacterial strains: Latest research developments and future perspectives. *Molecules* 2021;26:2671.
6. Gupta V, Datta P. Next-generation strategy for treating drug resistant bacteria: Antibiotic hybrids. *Indian J Med Res* 2019;149:97-106.
7. Baker SJ, Payne DJ., Rappuoli R, De Gregorio E. Technologies to address antimicrobial resistance. *Proc Natl Acad Sci U S A* 2018;115:12887-95.
8. Andersson DI, Balaban NQ, Baquero F, Courvalin P, Glaser P, Gophna U, *et al.* Antibiotic resistance: Turning evolutionary principles into clinical reality. *FEMS Microbiol Rev* 2020;44:171-88.
9. Anyaegbunam NJ, Anekpo CC, Anyaegbunam ZK, Doowuese Y, Chinaka CB, Odo OJ, *et al.* The resurgence of phage-based therapy in the era of increasing antibiotic resistance: From research progress to challenges and prospects. *Microbiol Res* 2022;264:127155.
10. Dutescu IA, Hillier SA. Encouraging the development of new antibiotics: Are financial incentives the right way forward? A systematic review and case study. *Infect Drug Resist* 2021;14:415-34.